TG Therapeutics and Rhizen Pharmaceuticals have collaborated to develop and commercialise Rhizen PI3K delta inhibitor, TGR-1202 previously referred as RP5264.
As part of the collaboration, the companies will develop TGR-1202 on a worldwide basis, excluding India, in the areas of hematologic malignancies and autoimmune disease.
Rhizen will also contribute backup molecules for TG to develop differentiated therapies.
TG Therapeutics executive chairman and interim CEO Michael Weiss said TG Therapeutics is excited to enter into collaboration with Rhizen Pharmaceuticals, whose innovative pre-clinical development program has yielded an impressive portfolio of PI3K delta inhibitors that the company is eager to advance into development.
"TGR-1202 has already demonstrated encouraging pre-clinical activity, and will serve to expand our pipeline as we seek to develop much needed therapies for patients suffering from hematologic malignancies," Weiss added.
Rhizen Pharmaceuticals president Swaroop Vakkalanka said, "The deep clinical and regulatory development knowledge and experience of the team at TG Therapeutics, and the existing clinical program focused on B-cell malignancies, makes TG an ideal partner with which to collaborate on development of TGR-1202."
TG Therapeutics will contribute up-front licensing payments and milestones based on early clinical development and will also be responsible for clinical development costs of the products through Phase II.
The collaboration and licensing payments are expected to cross $250m, according to TG Therapeutics.
